Bracco Diagnostics, Inc.

Find your local rep.

The Evidence Builds:
Relaxivity Matters1–4

Three independent, multicenter, intraindividual, crossover studies have proven that MultiHance’s highest relaxivity for CNS MRI matters, when compared to Magnevist® (gadopentetate dimeglumine), OMNISCAN (gadodiamide)
and now, Gadavist (gadobutrol).1–4

MultiHance and Magnevist comparison

*These are representative images from a multicenter, intraindividual double-blind randomized crossover comparative reference study (n=157) with statistically significant results of p values < 0.0001, individual results may vary.

Multihance compared to Magnevist

MultiHance injection, 529 mg/mL has a significantly greater relaxivity, and provides statistically significant (p <0.0001) better lesion contrast enhancement and diagnostic information in MRI of CNS lesions compared to Magnevist injection at 0.1 mmol/kg when a preference was expressed by blinded readers.1

Download abstract

MultiHance and OMNISCAN comparison

*These are representative images from a multicenter, intraindividual double-blind randomized crossover comparative reference study (n=138) with statistically significant results of p values < 0.0001, individual results may vary.

Multihance compared to OMNISCAN

MultiHance provided significantly improved CNS lesion enhancement and visualization as well as greater quantitative lesion-to-brain enhancement than OMNISCAN injection at 0.1 mmol/kg, when a preference was expressed by blinded readers.2

Download abstract

MultiHance and Gadavist comparison

*These are representative images from a multicenter, intraindividual double-blind randomized crossover comparative reference study (n=114) with statistically significant results of p values < 0.0001, individual results may vary.

Multihance compared to Gadavist

Significantly greater morphologic information and lesion enhancement was achieved on brain MRI with MultiHance compared to Gadavist at equivalent dose of 0.1 mmol/kg, when a preference was expressed by blinded readers. Superior contrast enhancement and better delineation of lesions and/or lesion internal structures were found.3

Download abstract

REFERENCES: 1. Maravilla KR, et al. Contrast enhancement of central nervous system lesions: multicenter intraindividual crossover comparative study of two MR contrast agents. Radiology. 2006;240:389-400. 2. Rowley HA, Scialfa G, Gao PY, et al. Contrast-enhanced MR imaging of brain lesions: a large-scale intraindividual crossover comparison of gadobenate dimeglumine versus gadodiamide. Am J Neuroradiology. 2008;29:1684-91. 3. Seidl Z, et al. Does Higher Gadolinium Concentration Play a Role in the Morphologic Assessment of Brain Tumors? Results of a Multicenter Intraindividual Crossover Comparison of Gadobutrol versus Gadobenate Dimeglumine (the MERIT Study). AJNR. Published online before print March 1, 2012, doi: 10.3174/ajnr.A3033. 4. MultiHance (gadobenate dimeglumine) injection, 529 mg/mL full Prescribing Information. Princeton, NJ: Bracco Diagnostics Inc. July 2011.

INDICATIONS AND USAGE
MultiHance is indicated for intravenous use in magnetic resonance imaging (MRI) of the central nervous system (CNS) in adults and children over 2 years of age to visualize lesions with abnormal blood brain barrier or abnormal vascularity of the brain, spine, and associated tissues.

IMPORTANT SAFETY INFORMATION

INDICATIONS AND USAGE
MultiHance is indicated for intravenous use in magnetic resonance imaging (MRI) of the central nervous system (CNS) in adults and children over 2 years of age to visualize lesions with abnormal blood brain barrier or abnormal vascularity of the brain, spine, and associated tissues.

IMPORTANT SAFETY INFORMATION